The application of cassette dosing for pharmacokinetic screening in small-molecule cancer drug discovery
暂无分享,去创建一个
[1] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[2] X. Tong,et al. High-throughput pharmacokinetics screen of VLA-4 antagonists by LC/MS/MS coupled with automated solid-phase extraction sample preparation. , 2004, Journal of pharmaceutical and biomedical analysis.
[3] C. Laggner,et al. Why drugs fail--a study on side effects in new chemical entities. , 2005, Current pharmaceutical design.
[4] Xavier Barril,et al. Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. , 2005, Journal of medicinal chemistry.
[5] R E White,et al. Pharmacokinetic theory of cassette dosing in drug discovery screening. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[6] K. Adkison,et al. Simultaneous pharmacokinetic screening of a mixture of compounds in the dog using API LC/MS/MS analysis for increased throughput. , 1997, Journal of medicinal chemistry.
[7] D. Brewster,et al. Trends in cancer incidence and mortality in Scotland: description and possible explanations. , 1998, British Journal of Cancer.
[8] P. Workman,et al. Finding the needle in the haystack: why high-throughput screening is good for your health , 2002, Breast Cancer Research.
[9] P. Griffin,et al. Determination of brain and plasma drug concentrations by liquid chromatography/tandem mass spectrometry. , 2000, Rapid communications in mass spectrometry : RCM.
[10] L. Cohen,et al. Evaluation of online extraction/mass spectrometry for in vivo cassette analysis. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[11] Martin Vogel,et al. LC/MS Applications in Drug Development , 2002 .
[12] R. W. Hansen,et al. The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.
[13] P. Workman. How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. , 2003, Current pharmaceutical design.
[14] E. Kanaoka,et al. A new generic column switching system for quantitation in cassette dosing using LC/MS/MS. , 2003, Journal of pharmaceutical and biomedical analysis.
[15] D S Wright,et al. Sample pooling to expedite bioanalysis and pharmacokinetic research. , 1998, Journal of pharmaceutical and biomedical analysis.
[16] Walter A. Korfmacher,et al. HPLC-API/MS/MS : a powerful tool for integrating drug metabolism into the drug discovery process , 1997 .
[17] Evans,et al. Approaches to higher-throughput pharmacokinetics (HTPK) in drug discovery. , 2000, Drug discovery today.
[18] P. Workman,et al. Design and development of signal transduction inhibitors for cancer treatment: Experience and challenges with kinase targets , 2006 .
[19] H. Zeng,et al. The investigation and the use of high flow column-switching LC/MS/MS as a high-throughput approach for direct plasma sample analysis of single and multiple components in pharmacokinetic studies. , 2002, Journal of pharmaceutical and biomedical analysis.
[20] Walter A. Korfmacher,et al. Rapid determination of pharmacokinetic properties of new chemical entities: in vivo approaches. , 2002, Combinatorial chemistry & high throughput screening.
[21] N. J. McNally,et al. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). , 1998, British Journal of Cancer.
[22] A. John Bailer,et al. Testing for the equality of area under the curves when using destructive measurement techniques , 1988, Journal of Pharmacokinetics and Biopharmaceutics.
[23] Paul Workman,et al. Pharmacodynamic biomarkers for molecular cancer therapeutics. , 2007, Advances in cancer research.
[24] M. Drysdale,et al. Preclinical pharmacokinetics and metabolism of a novel diaryl pyrazole resorcinol series of heat shock protein 90 inhibitors , 2006, Molecular Cancer Therapeutics.
[25] G. Hopfgartner,et al. Quantitative high-throughput analysis of drugs in biological matrices by mass spectrometry. , 2003, Mass spectrometry reviews.
[26] F. Russel,et al. Screening for the role of transporters in hepatic and renal drug handling. , 2004, Drug discovery today. Technologies.
[27] T. Olah,et al. The simultaneous determination of mixtures of drug candidates by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry as an in vivo drug screening procedure. , 1997, Rapid communications in mass spectrometry : RCM.
[28] H. Varmus,et al. Oncogenes come of age. , 2005, Cold Spring Harbor symposia on quantitative biology.
[29] L. Kuo,et al. Combinatorial diversification of indinavir: in vivo mixture dosing of an HIV protease inhibitor library. , 2000, Bioorganic & medicinal chemistry letters.
[30] Mei-Yi Zhang,et al. Determination of rat oral bioavailability of soy-derived phytoestrogens using an automated on-column extraction procedure and electrospray tandem mass spectrometry. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[31] Paul Workman,et al. CHAPTER 14 – MECHANISM-BASED HIGH-THROUGHPUT SCREENING FOR NOVEL ANTICANCER DRUG DISCOVERY , 2002 .
[32] Sample pooling to enhance throughput of brain penetration study. , 1999, Journal of pharmaceutical and biomedical analysis.
[33] S. Clarke,et al. In vitro and In vivo Pharmacokinetic-Pharmacodynamic Relationships for the Trisubstituted Aminopurine Cyclin-Dependent Kinase Inhibitors Olomoucine, Bohemine and CYC202 , 2005, Clinical Cancer Research.
[34] T. Kennedy. Managing the drug discovery/development interface , 1997 .
[35] J. Yuan,et al. Estimation of variance for AUC in animal studies. , 1993, Journal of pharmaceutical sciences.
[36] Sonu Sundd Singh,et al. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. , 2006, Current drug metabolism.
[37] Cox,et al. Novel procedure for rapid pharmacokinetic screening of discovery compounds in rats. , 1999, Drug discovery today.
[38] T G Myers,et al. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. , 1999, Journal of the National Cancer Institute.
[39] P. Woollard,et al. Cassette dosing: rapid in vivo assessment of pharmacokinetics , 1998 .
[40] D. Lane,et al. Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine cyclin-dependent kinase 2 inhibitors prepared by parallel synthesis. , 2004, Molecular cancer therapeutics.
[41] S. Lakhani,et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] A. Sparreboom,et al. Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination , 2005, Expert opinion on drug metabolism & toxicology.
[43] P. Workman. Drugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeutics. , 2005, Cold Spring Harbor symposia on quantitative biology.
[44] T. Olah,et al. A direct technique for the simultaneous determination of 10 drug candidates in plasma by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry interfaced to a Prospekt solid-phase extraction system. , 1997, Journal of pharmaceutical and biomedical analysis.
[45] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[46] J. Henion,et al. Atmospheric pressure ionization LC/MS/MS techniques for drug disposition studies. , 1998, Journal of pharmaceutical sciences.
[47] P. Workman. Challenges of PK/PD measurements in modern drug development. , 2002, European journal of cancer.
[48] Martin R. Johnson,et al. Discovery of further pyrrolidine trans-lactams as inhibitors of human neutrophil elastase (HNE) with potential as development candidates and the crystal structure of HNE complexed with an inhibitor (GW475151). , 2002, Journal of medicinal chemistry.
[49] C. Hop,et al. Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. , 1998, Journal of pharmaceutical sciences.
[50] K. Adkison,et al. Use of "N-in-One" dosing to create an in vivo pharmacokinetics database for use in developing structure-pharmacokinetic relationships. , 1999, Journal of pharmaceutical sciences.
[51] P. Janser,et al. A cassette-dosing approach for improvement of oral bioavailability of dual TACE/MMP inhibitors. , 2006, Bioorganic & medicinal chemistry letters.
[52] P. Workman. Genomics and the second golden era of cancer drug development. , 2005, Molecular bioSystems.
[53] M. Kansy,et al. Advances in screening for membrane permeability: high-resolution PAMPA for medicinal chemists. , 2004, Drug discovery today. Technologies.
[54] P. Workman,et al. Evaluation of the cassette dosing approach for assessing the pharmacokinetics of geldanamycin analogues in mice , 2004, Cancer Chemotherapy and Pharmacology.
[55] L. Pearl,et al. High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. , 2004, Analytical biochemistry.
[56] A. Ungell. Caco-2 replace or refine? , 2004, Drug discovery today. Technologies.
[57] S. Walker,et al. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). , 1988, British journal of clinical pharmacology.
[58] Paul Workman,et al. The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. , 2005, Bioorganic & medicinal chemistry letters.
[59] Simon A Roberts. Drug metabolism and pharmacokinetics in drug discovery. , 2003, Current opinion in drug discovery & development.
[60] M. Drysdale,et al. Discovery and development of pyrazole-scaffold Hsp90 inhibitors. , 2006, Current topics in medicinal chemistry.
[61] W. Day,et al. Rapid Determination of Oral Pharmacokinetics and Plasma Free Fraction Using Cocktail Approaches: Methods and Application , 2004, Pharmaceutical Research.
[62] P. Workman,et al. Gene expression microarray technologies in the development of new therapeutic agents. , 2004, European journal of cancer.
[63] Ronald E White,et al. Whatever happened to cassette-dosing pharmacokinetics? , 2004, Drug discovery today.
[64] K. Subramanian. truPK – human pharmacokinetic models for quantitative ADME prediction , 2005, Expert opinion on drug metabolism & toxicology.
[65] M K Bayliss,et al. High-throughput pharmacokinetics: cassette dosing. , 1999, Current opinion in drug discovery & development.
[66] E. Sausville,et al. Clinical development of 17-allylamino, 17-demethoxygeldanamycin. , 2003, Current cancer drug targets.
[67] Walter A. Korfmacher,et al. Novel in vivo procedure for rapid pharmacokinetic screening of discovery compounds in rats , 1999 .
[68] M. Lee,et al. LC/MS applications in drug development. , 2002, Mass spectrometry reviews.
[69] M. Egorin,et al. Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. , 1998, Cancer research.
[70] M. Drysdale,et al. Inhibitors of HSP90 and other chaperones for the treatment of cancer , 2004 .
[71] R. Gupta,et al. A high throughput approach for simultaneous estimation of multiple synthetic trioxane derivatives using sample pooling for pharmacokinetic studies. , 2005, Journal of pharmaceutical and biomedical analysis.
[72] P. Workman. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones , 2003, Cancer Chemotherapy and Pharmacology.
[73] S. Potkay,et al. Frequently asked questions about the public health service policy on humane care and use of laboratory animals. , 2003, Lab animal.
[74] Walter A. Korfmacher,et al. Cassette-accelerated rapid rat screen: a systematic procedure for the dosing and liquid chromatography/atmospheric pressure ionization tandem mass spectrometric analysis of new chemical entities as part of new drug discovery. , 2001, Rapid communications in mass spectrometry : RCM.
[75] L. Benet,et al. Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes. , 2004, Drug metabolism and disposition: the biological fate of chemicals.
[76] Kiyoshi Hasegawa,et al. Cassette Dosing Approach and Quantitative Structure-Pharmacokinetic Relationship Study of Antifungal N-Myristoyltransferase Inhibitors , 2002, J. Chem. Inf. Comput. Sci..
[77] L. Jia,et al. Simultaneous estimation of pharmacokinetic properties in mice of three anti-tubercular ethambutol analogs obtained from combinatorial lead optimization. , 2005, Journal of pharmaceutical and biomedical analysis.
[78] D. Lane,et al. Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse. , 2005, Molecular cancer therapeutics.
[79] R. Riley,et al. Metabolic screening in vitro: metabolic stability, CYP inhibition and induction. , 2004, Drug discovery today. Technologies.
[80] J. T. Wu,et al. Direct plasma sample injection in multiple-component LC-MS-MS assays for high-throughput pharmacokinetic screening. , 2000, Analytical chemistry.
[81] R. Gupta,et al. LC fluorescence method for multiple synthetic compounds to rapidly create in vivo pharmacokinetic database utilizing 'N-in-One' dosing. , 2001, Journal of pharmaceutical and biomedical analysis.
[82] Matthew Segall,et al. In silico prediction of ADME properties: are we making progress? , 2004, Current opinion in drug discovery & development.